Exdensur

Understanding Exdensur
Exdensur (depemokimab-ulaa) injection, for subcutaneous use, is a prescription biologic medicine classified as an interleukin‑5 (IL‑5) antagonist monoclonal antibody (humanized IgG1 kappa). It is indicated as an add‑on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients 12 years of age and older whose disease remains uncontrolled on standard therapies. Exdensur is supplied as an injection solution for subcutaneous administration and is not intended for the relief of sudden breathing problems, acute bronchospasm, or status asthmaticus.

How Exdensu Works:

• Targeted IL‑5 pathway inhibition: Exdensur is an IL‑5 antagonist monoclonal antibody that binds to interleukin‑5, thereby interfering with IL‑5–mediated signaling involved in the development, activation, and survival of eosinophils, a type of white blood cell that contributes to airway inflammation in eosinophilic asthma.
• Reduction of eosinophilic inflammation and exacerbations: By lowering eosinophil levels and attenuating eosinophilic airway inflammation, Exdensur has been shown in phase 3 SWIFT‑1 and SWIFT‑2 trials to reduce the rate of asthma exacerbations when used in addition to standard of care in appropriate patients with severe asthma and an eosinophilic phenotype.
• Ultra‑long‑acting maintenance dosing: Exdensur is designed as a long‑acting biologic with a recommended dose of 100 mg administered once every 6 months as a subcutaneous injection into the upper arm, thigh, or abdomen. This twice‑yearly regimen, given by a healthcare provider, offers an infrequent maintenance dosing schedule for eligible patients with severe eosinophilic asthma.
• Administration context: Exdensur is used as an add‑on maintenance therapy alongside a patient’s existing asthma treatment regimen, including inhaled corticosteroids and other controllers, as appropriate. Injections are administered by a trained healthcare professional, with ongoing monitoring and follow‑up guided by the full prescribing information, clinical response, and the treating clinician’s judgment. Exdensur should not be used to treat acute bronchospasm or status asthmaticus.

FDA Approval:

2025 – Exdensur (depemokimab-ulaa) injection, for subcutaneous use, was approved by the U.S. Food and Drug Administration as an add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. It is the first ultra‑long‑acting biologic with twice‑yearly dosing approved for this patient population.

For more information, please visit the Exdensu patient website. Speak with your healthcare provider to determine if Exdensu is the right treatment option for you.